Literature DB >> 15688969

Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide.

Meher Yepremyan1, Fleming D Wertz, Tim Tivnan, Laura Eversman, Jeffrey L Marx.   

Abstract

BACKGROUND AND
OBJECTIVE: To determine the efficacy of intravitreal triamcinolone acetonide (IVTA) in the early treatment of severe cystoid macular edema (CME) related to acute branch retinal vein occlusion. PATIENTS AND METHODS: Retrospective, non-comparative case series. Twelve eyes with severe CME (foveal thickness > 450 microm) secondary to acute branch retinal vein occlusion received IVTA.
RESULTS: Average follow-up was 15.3 months. Mean visual acuity was 0.88 LogMar units (20/160) initially, 0.55 LogMar units (20/70) at 1 week, 0.46 LogMar units (20/60) at 1 month, and 0.49 LogMar units (20/60) at last follow-up. Visual acuity improved by 3 lines or greater in 42% of patients at 1 week, 50% at 1 month, and 42% at last follow-up. Average foveal thickness was 589 microm (range, 460 to 840 microm) at baseline, 237 microm at 1 week, 196 microm at 1 month, and 235 microm at last follow-up. All eyes showed reduction of foveal thickness as measured by optical coherence tomography. Eight eyes developed recurrent CME at an average of 5.5 months after initial IVTA injection. Ten eyes required additional intervention during the follow-up period.
CONCLUSIONS: Early treatment of severe CME secondary to branch retinal vein occlusion with IVTA is effective in reducing foveal thickness as measured by optical coherence tomography and improving visual acuity. However, monotherapy with IVTA can be associated with a significant rate of recurrent CME.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688969

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  7 in total

1.  Arteriovenous sheathotomy for persistent macular edema in branch retinal vein occlusion.

Authors:  Joon Hong Sohn; Su Jeong Song
Journal:  Korean J Ophthalmol       Date:  2006-12

2.  Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis).

Authors:  Gary Edd Fish
Journal:  Trans Am Ophthalmol Soc       Date:  2008

3.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.

Authors:  Ingrid U Scott; Michael S Ip; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Clement K Chan; Victor H Gonzalez; Lawrence J Singerman; Michael Tolentino
Journal:  Arch Ophthalmol       Date:  2009-09

4.  Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial.

Authors:  Alireza Ramezani; Morteza Entezari; Siamak Moradian; Shohreh Kadkhodaei; Homa Tabatabaei; Babak Dehsarvi; Mohammad Fatehi; Mehdi Yaseri
Journal:  J Ophthalmic Vis Res       Date:  2011-04

5.  Early versus late intravitreal triamcinolone acetonide for macular edema associated with branch retinal vein occlusion.

Authors:  Joo Youn Oh; Je Hyun Seo; Jae Kyoun Ahn; Jang Won Heo; Hum Chung
Journal:  Korean J Ophthalmol       Date:  2007-03

6.  Use of intravitreal triamcinolone in the treatment of macular edema related to retinal vein occlusion.

Authors:  Ashish Sharma; Baruch D Kuppermann; M Cristina Kenney
Journal:  Open Ophthalmol J       Date:  2008-04-07

Review 7.  Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.

Authors:  Jiri Rehak; Matus Rehak
Journal:  Curr Eye Res       Date:  2008-02       Impact factor: 2.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.